Aripiprazole Tablet
Product Images NDC 63187-965

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 63187-965). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

Chemical structure diagram of Aripiprazole demonstrating the arrangement of chlorine-substituted aromatic rings and the piperazine moiety linked to a quinolinone group, consistent with the active ingredient Aripiprazole.*

FDA Label Image

63187-965-30 (Aripiprazole Tablets 10)

Label for Aripiprazole 2 mg oral tablets by Proficient Rx LP, NDC 63187-965-30. The label indicates a package containing 30 tablets. Tablets are described as green to light green, mosaic appearance, modified rectangle shape, uncoated, with debossing 'AN896' and '2' on one side. Manufacturer is Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad, India.*

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

A pharmacokinetic chart showing the effect of various drugs on Aripiprazole's fold change in AUC and Cmax with 90% confidence intervals. It compares interactions with CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs relative to reference levels without interacting drugs.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals for dehydro-aripiprazole levels. The chart compares AUC and Cmax values under the influence of various interacting drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam), with reference to no interacting drug.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

A scatter plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs metabolized by enzymes such as CYP2D6, CYP2C9, 2C19, and UGT1A4. The x-axis represents the change relative to reference (without interacting drug) from 0.5 to 3.0, while the y-axis lists different drugs like dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram with pharmacokinetic parameters AUC and Cmax indicated. Data points show variable influence of Aripiprazole on these drugs' pharmacokinetics.*

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax for various special populations including CYP2D6 poor vs. extensive metabolizers, gender (female vs. male), age groups (18-64 vs. >65 years old), hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment, relative to reference values.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

A pharmacokinetic chart showing the fold change and 90% confidence intervals of Dehydro-Aripiprazole across various factors. The x-axis represents change relative to reference, while the y-axis lists factors such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with separate measures for AUC and Cmax. Data points with error bars illustrate variability in these subgroups.*

FDA Label Image

Fig-6 (Aripiprazole Tablets 7)

A Kaplan-Meier curve comparing the proportion with relapse over days from randomization for Aripiprazole and placebo groups. The graph shows relapse proportions on the vertical axis and days from randomization on the horizontal axis. Aripiprazole is represented by a solid blue line and placebo by a dashed red line, with subject numbers at risk listed below the x-axis.*

FDA Label Image

01 (Aripiprazole Tablets 8)

A Kaplan-Meier relapse proportion graph comparing Aripiprazole and placebo over 182 days from randomization. The x-axis shows days, the y-axis displays proportion with relapse. Two curves represent relapse rates, with accompanying numbers of subjects at risk for each treatment group at intervals along the x-axis.*

FDA Label Image

0102 (Aripiprazole Tablets 9)

A Kaplan-Meier curve comparing the proportion of subjects with relapse over 364 days from randomization between two groups: Aripiprazole and placebo. The solid line represents Aripiprazole, and the dashed line represents placebo. Below the x-axis is a table showing the number of subjects at risk at different time points for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.